Chong Kun Dang Pharm Licenses Synaffix ADC Technology, Adds Novel ADC Candidate to Oncology Pipeline

 

•  Synaffix to provide access to proprietary Antibody-Drug Conjugate (ADC) technologies
• Single-target license with upfront and milestone payments plus royalties
• First Synaffix partnership announced with a Korean company

Read more…